Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
Cell-free concentrated ascites reinfusion therapy enables removal of extracellular vesicles and circulating immune complexes in ascites.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamaji Yu, Murayama Goh, Inoue Moeko, Urita Takuya, Hirayama Takashi, Uchiyama Akira, Nojima Masaki, Hagiwara Yukitomo, Saito Takumi, Kuga Taiga, Miyashita Tomoko, Kusaoi Makio, Terao Yasuhisa, Itakura Atsuo, Ikejima Kenichi, Tamura Naoto, Yamaji Ken
Аннотация
INTRODUCTION: Cell-free and concentrated ascites reinfusion therapy (CART) is used for ascites in decompensated cirrhosis and malignant tumors. We investigated extracellular vesicles (EVs) and circulating immune complexes (CICs) as potential inflammatory inducers in ascites and verified whether they can be removed through CART treatment.
METHODS: Ascites from 10 patients, including those with cancer, undergoing CART were analyzed. We compared the inflammatory inducers in untreated ascites, ascites processed using AHF-MO (conventional CART filter), and those filtered with EC20W (double-filtration plasmapheresis filter). A cell-based reporter assay measured biological activity.
RESULTS: AHF-MO significantly lowered EV and CIC levels along with physiological activity in the treated ascites. EC20W was superior in terms of EV removal but showed no significant difference from AHF-MO in CIC removal. AHF-MO showed a greater reduction in physiological activity.
CONCLUSION: The CART process with AHF-MO effectively removes EVs and CICs, reducing physiological activity and demonstrating its safety in ascites treatment.
METHODS: Ascites from 10 patients, including those with cancer, undergoing CART were analyzed. We compared the inflammatory inducers in untreated ascites, ascites processed using AHF-MO (conventional CART filter), and those filtered with EC20W (double-filtration plasmapheresis filter). A cell-based reporter assay measured biological activity.
RESULTS: AHF-MO significantly lowered EV and CIC levels along with physiological activity in the treated ascites. EC20W was superior in terms of EV removal but showed no significant difference from AHF-MO in CIC removal. AHF-MO showed a greater reduction in physiological activity.
CONCLUSION: The CART process with AHF-MO effectively removes EVs and CICs, reducing physiological activity and demonstrating its safety in ascites treatment.